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ABSTRACT Cancer, in spite of several years of research and consequent improvements in clinical management of
the disease, shows limited decline in the associated patient mortality and morbidity. In order to achieve better and
early diagnosis, design appropriate treatment strategies and precise prognostication, molecular markers which could
subclassify tumors are being assessed to complement TNM classification.  Plethora of information is spilling out from
the recent high-throughput technologies for global profiling. Time has come to assess the technologies, study designs
and data processing to obtain information which is clinically relevant. This review analyses the state of the art in
Cancer Proteomics and the issues, which need to be addressed to move the technology from the bench to the bedside.
Cancer Proteomics is the application of
proteomics technology to identify qualitative and
quantitative differences in proteins detected in
the tumor tissue or other relevant body fluids of
a patient with cancer versus those in healthy
individuals, to aid in cancer diagnosis, prognosti-
cation and treatment more effectively.
Conventional  Clinical  Classification  and
Need  for  Markers
Cancer, in spite of several years of research
and consequent improvements in clinical
management of the disease, shows limited decline
in the associated patient mortality and morbidity.
Several reasons limit the success of strategies
for cancer management. One and very important
is that it is a heterogenous disease. Even within
a single cancer site, tumors have markedly diff-
erent behaviours and are associated with widely
varying prognoses. Till date the most widely used
guideline for prognostication in cancer medicine
has been the TNM staging, which is based on
anatomical extent of the disease. It provides a
basis for prediction of survival, choice of initial
treatment and stratification of patients in clinical
trials (www.cancerstaging. org).
In recent years, molecular markers which
could further subclassify tumors have been
assessed to complement TNM classification to
bring precision to prognostication (Ludwig and
Weinstein 2005). Secondly, the heterogeneity of
disease fails a common treatment regimen. Even
in a given patient, the genetic instability of
invasive cancer means that combination of
therapeutic agents will probably be required to
prevent a cell from developing resistance to the
targeted therapeutics. Thus additional targets
for therapy need to be identified (Maitland et al.
2006; Corchero and Fernandes-Salguero 2005;
Manne et al. 2005 ).  Lastly, most people who
develop cancer have advanced disease at the
time of diagnosis. Survival rates for people
diagnosed with advanced cancer have changed
little over the past 20 years. At this time,
therapeutic modalities are very limited in their
success and most of treatment is spent providing
palliative quality of life therapy. By contrast,
survival is relatively good when these cancers
are diagnosed at an early stage. Tools for early
detection are therefore necessary (Sciubba 2001;
Hirsch et al 2002).
Analysis of molecular alterations, in DNA,
RNA or proteins in cells undergoing malignant
transformation have increasingly revealed
individual molecules that are associated with
malignant transformation, some of them have
been shown to be related to tumor stage and
grading or may be indicative for the prognosis
and the clinical course of the disease. They cover
molecules associated with various aspects of
tumor biology such as cell cycle control (Colozza
et al 2005), apoptosis (Thomadaki et al. 2006),
matrix degradation, adhesion molecules and
immunologic tumor defense (Chin et al. 2005;
Whiteside 2004). US Food and Drug Adminis-
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tration has approved several clinically relevant
biomarkers-mainly proteins, such as human
chorionic gonadotropin β  for staging of testicular
carcinomas and expression of oestrogen and
progesterone receptors for selection of hormonal
therapy for breast cancer (Ludwig and Weinstein
2005). Chromosomal markers have found
application in diagnosis of leukemias (Kim 2004
), bladder cancer and breast cancer (Ludwig and
Weinstein 2005).
In the clinics, these molecular biomarkers
are supplementing the already existing tools for
cancer diagnosis and disease management. Their
utility is however limited by several factors.
Conceptually, from the point of view of
tumorigenesis, the cancer phenotype results from
the sum total of the effects of all the numerous
contributing transformed loci. Over two decades
of investigations have shown that an alteration
in many different genes, each with an allelic
variation, contributes to the total observed
variability and heterogeneity, which is impossible
to assess by studying single markers. This is
reflected in lack of absolute predictability for a
single or a set of markers (Caprioli 2005). When
their expression is tested in biological samples, a
grey zone exists for samples, which fall in the
zone overlapping the expression in control and
the test, wherein decision-making is difficult
(Baker 2005).
More recently, battery of biomarkers are being
increasingly viewed as more accurate than
individual biomarkers (Mitra et al. 2005).
Biostatisticians have long known that clusters
of variables can be used to differentiate two sets.
Co-expression of a combination of these markers
have been successfully applied to stratify
patients. For examples USFDA has approved
oncotype Dx test, which assesses tumor
expression of 21 genes, to predict potential of
breast tumors to recur and respond to therapy
(Baker 2005). More recently, the cytochrome P
450 genotyping test to assess drug metabolism
has become available (Hanash 2004). Moreover,
technologies established for global profiling of
macromolecues like CGH, microarray and
proteomic analysis have eliminated the need for
prior knowledge of markers or confounding of
results by biased selection of known markers.
For example in a microarray set up, expression of
thousands of genes can be assessed in a single
experiment, making the matrix of markers large
enough to allow subclassification (Dahl et al.
2006; Wong et al. 2006; Kim 2004). During the
past decade, genomic microarrays have been
applied with great success to the molecular
profiling of tumours, which has resulted in a much
more detailed classification scheme as well as in
the identification of potential gene signature sets
(Mayr et al. 2006; Patil et al. 2005).
 In the post-genomics era, the significance
of protein profiling for deciphering functional
pathways in cell physiology and their aberrations
in pathology is widely acknowledged and
receiving immense attention for early detection,
diagnosis and prognosis. The key proteins
driving oncogenesis undergo translation and
post-translational modifications, which are not
reflected in their transcription or genomic
profiles. Since proteins are the most effective drug
targets, their profiling and understanding of the
functional pathways altered in tumor would
provide additional or new targets for therapy.
Moreover, when response to therapy is to be
assessed, it will be necessary to analyze proteins
in readily accessible serum samples and other body
fluids, since repeat biopsies are not a realistic
option.  Therefore, if individualization of therapy
is to move into the practical world, blood-based
assays, serum and body fluid proteomics become
critical (Abramovitz and Leyland – Jones 2006). In
this context, the utility of immunoproteomics to
analyse autoantibody response in patients with
cancer is an area under intense investigation
(Anderson and LaBaer 2005; Casiano et al 2006).
Proteomic Technologies useful in Clinical
Cancer Research
Global profiling of proteins in tissues and
body fluids has been limited by the number of
proteins, out of the 40,000 expressed by the
genome that could be separated and detected by
the present technology. On-going technological
improvisations are trying to meet this challenge.
Several new technologies are available and
emerging to either discover combinatorial
biomarkers or validate the known as well as new
biomarkers in a translational mode. They are
reviewed in detail (Misek et al. 2004; Conrads et
al. 2004; Lim and Elenitoba-Johnson 2004;
Srinivas et al. 2001; Nair et al. 2004; Petricoin et
al. 2004) and are summarized below based on the
concept of application.
Biological mass spectrometry (MS) has
revolutionized the field of protein profiling.CLINICAL CANCER PROTEOMICS 93
Variety of instruments with distinct resolution,
sensitivity and mass accuracy are now available
which can identify proteins by peptide mass
fingerprinting or de-novo sequencing (Solassol
et al. 2006) .
Analysis of protein mixtures like tissue
lysates and body fluids, requires their prior
separation to reduce the complexity. These
methods separate proteins on the basis of charge
and/or molecular weight. A commonly used
method is two dimensional gel electrophoresis.
Sensitivity of detection in 2D electrophoresis is
limited by that of separation and staining by the
practically achievable dimensions of the gel,
limiting their use for the detection of mostly high
abundance proteins in a non-prefractionated
sample. Comparison of spots in control and test
gels even with the available softwares have
practical limitations which has not improved
greatly in the co-electrophoresed test and control
samples labeled differentially with fluorescent
dyes (Ornstein and Petricoin 2004). Another
method of protein separation is liquid
chromatography, in which column with proper-
ties to bind protein/peptides with specific charac-
teristics are employed singly or in combination
to separate highly complex protein mixtures. This
method is useful for separation of low-abun-
dance proteins (Frohlich and Arnold 2006). The
differentiators in control and test samples could
be analysed in a single run using the differential
labeling techniques like ICAT (Turecek 2002) as
well as ITRAQ (Aggrawal et al. 2006)
Separation of proteins can also be achieved in
a mass spectrometry system with the SELDI
technology wherein protein chips are available
for a variety of different chromatographic surfaces
that are designed to retain specific classes of
proteins based on physicochemical properties
such as hydrophobicity and charge. The approach
has found wide application in clinical proteomics
but of late has also received criticism as a
technique (Ardekani et al 2002; Engwegen et al.
2006). SELDI analysis of peripheral blood plasma
has generated a molecular profile that gives a
strong positive prediction of recurrence in ALL
(Albitar et al. 2006) as also prognostic markers for
node-negative breast cancer patients (Ricolleau
et al 2006)
Proteins can be detected in samples
individually or in combinations with simpler
methodologies, provided specific antibody/
antibodies are available for each protein. This
approach is being used for validation of markers
or for developing clinical tests that are easy to
perform in diagnostic laboratories using
techniques such as multiwestern immunoblotting
and antibody /protein arrays for the analysis of
proteins in tissue lysates and body fluids.
Antibody detection of molecules in tissue
sections or in tissue arrays is achieved by
immunohistochemistry (IHC). The Swedish
Human Proteome Resource Project (www.hpr.se)
with its target to generate antibodies for all
annotated proteins will contribute immensely
towards these efforts (Uhlen 2005).  Beyond
separated protein mixtures, whole tissue MALDI
is now projected as the next sensitive technology
that can be used in a clinical set up (Caldwell and
Caprioli 2005).
Lot of data has emerged using the above
mentioned proteomics technologies and statistics
is being used to evaluate the co-expression
patterns of differentiators for their biological
relevance. To state a few representative examples,
Dwek and Alaiya (2003), Alaiya et al. (2002),
Hellman et al. (2004) have achieved segregation
of normal tissue, benign epithelium and tumor
tissue in breast, ovary and vagina respectively.
The potential of the proteomic approaches is
apparently multifarious. However, the sensitivity
and specificity of prediction needs further
refinement of concept and technology. This is
achievable if certain nuances in experimental
design and data analysis are considered and
given intense attention to address the lacunae.
Experimental Designs that Need Attention
The areas which need attention are the
consideration of cancer as a systemic disease,
the reductionist approach where necessary,
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optimal selection of sample and sample size,
appropriate statistical or computational
analysis for the co-expression of markers, beyond
quantitative and qualitative alterations into
altered localization, both subcellular and within
the tissue sample and molecular alterations such
as post-translational modifications.
Cancer attains a systemic disease status as it
advances. Clonal expansion of the transformed
cell is a continuum of molecular alterations,
exposed to the extracellular microenvironment.
These molecules themselves or microenviron-
ment modified by them evoke responses in the
neighbouring or immune cells which in turn
facilitates tumor progression. Thus, the imprints
of the progressing disease extends out into the
microenvironment of the tumor-host interface,
the surrounding stromal and vascular compart-
ments and outwards, to the circulation
macroenvironment. While detection of markers
directly in tissue biopsy would correlate with the
primary disease, to get a complete picture of the
disease state it is essential to screen the tumor
tissue, surrounding stroma, serum and other
relevant body fluids for probable markers.  Such
a systems approach has been elegantly reviewed
for breast cancer by Abramovitz and Leyland-
Jones (2006).
The challenges of this approach and
meaningful analysis of complex data to yield
specificity, has on the other hand necessitated
the use of microdissected tumor tissue to identify
the contribution of the marker from each of the
sites towards the trasformation process. Reports
like detection of stathmin as a potential biomarker
for both tumors of salivary gland (Nakashima et
al. 2006)  and oral squamous cell carcinoma
(Kouzu et al. 2006) has necessitated confirmation
of  the finding in microdissected tissue (Rekhter
and Chen 2001).
Beyond the qualitative and quantitative
analysis of tumor markers which contribute to
the prognosis of the disease it has become
essential to assess  the location of these markers
within the tumor mass as well as its intracellular
localization. In particular, the invasive front of
the tumor appears to be of great importance for
prognostication as seen from the study by
(Abramovitz and Leyland- Jones 2006) which
shows that intratumoral rather than peritumoral
dendritic cells are often indicative of survival. In
colorectal carcinoma, tumor leading edge has
shown Ki 67 expression in the tumor cells (Rubio
2006) while cathepsin B is predominantly
expressed by macrophages at the leading edge
of the invading tumors (McKerrow et al. 2000) .
Such evaluations require investigations in several
areas of the tumor tissue, necessitating larger
representative tumour tissue samples rather than
just punch biopsies.  In this regard, the use of
tissue arrays for analysis of different areas of the
specimen needs careful consideration. Another
factor that needs attention is the intracellular
localization of the molecules and any alteration
in the tumor tissue which could have prognostic
significance. This is evident in a report wherein
nuclear localization of GST Pi, in the tumor tissue,
is useful in the prognostication of glioma (Ali-
Osman et al. 1997).
The posttranslational modification of
proteins, by phosphorylation, glycosylation,
ubiquitinylation, proteolytic cleavage etc and
sometimes consequential change in subcellular
location, as a cause/consequence of transforma-
tion also needs attention.  Petricoin et al (2005)
have provided a vision for individualized combi-
natorial therapy based on proteomic mapping of
phosphorylation end points in clinical tissue
material.
Assuming that not only tumorigenesis and
progression but also prognosis has a multi-
factorial molecular background, it is apparent that
larger samples sizes are more likely to escape
blurring of results due to uncontrolled effects and
thereby help in reaching statistical signi-ficance.
The low predictive value of those markers which
fail to reach significance may therefore in part be
accounted for by insufficient sample size
(Schliephake 2003; Lin and Kibbe 2005). Further,
sufficient sample size could underscore the
prognostic relevance of markers identified by IHC,
in spite of  the semiquantitative nature of the
analysis as shown by Lyall et al. (2006) in their
study of colon cancers. In a traditional multivariate
analysis, the ratio between sample size and number
of variables is suggested to be larger than 30:1.
With a small sample size and huge variable search
space, the probability of finding associations by
random chance is quite high even when analysed
at statistically stringent conditions (Lin and Kibbe
2005). The utility of Fuzzy logic in these situations
needs to be considered.
The expression level and molecular forms of
proteins are a consequence of genomic factors,
structural modifications, regulatory processes
involving cellular integration and balance (orCLINICAL CANCER PROTEOMICS 95
imbalance), environmental factors, temporal
processes etc. The net sum of these gives rise to
a proteome expression level and distribution that
reflects the integrated metabolic state of the cells
in that tissue at any given point in time as the
proteome is dynamic. (Nair et al. 2004). Therefore,
assessment of biomarkers in repeat biopsies is
necessary. This has practical limitations for
biopsy material, but could be overcome in the
analysis of markers in body fluids.
How Far are We from Clinic?
In the comparative proteomic approach for
marker identification, significant problems remain.
Most of the proteomics studies yield information
about molecules expressed in large amounts,
easily detected by the present technology. These,
more often than not are useful for determining
the transformed state and could be used in
diagnosis. The molecules, which would be
required for prognostication and/or are potential
therapeutic targets are expressed in lower
amounts. It is essential that the technology used
for profiling is sensitive enough to detect the
differentiators from both these categories.
Other parameters which can confound the
results could be the identification of markers that
reflect non-disease-specific systemic responses
of the patient or other secondary to the disease.
Several environmental factors such as diet and
tobacco habits can lead to complex and rapidly
changing protein patterns not directly related to
the primary disease.
It is becoming apparent that genomic and
proteomic technologies have the potential to
discriminate between subtypes of tumors.
Computational and mathematical techniques,
such as multivariate analysis or machine learning,
can pluck out differences or clusters of
differences that distinguish members of one
group from the other, at least for that particular
sample set. However, given enough variables,
some will discriminate the treatment group from
control groups by chance, with often mislead-
ingly impressive statistical significance.  Caution
is therefore necessary in these analyses and
validation of the sensitivity and specificity of
markers is obligatory. Biomarkers should be
confirmed in independent studies across
institutions before being used to make decisions
and the level of certainty required varies with the
biomarker.
Finally, to translate the validated battery of
markers into a viable laboratory test, certain issues
need to be addressed. The technological platforms
used for global proteomic profiling such as mass
spectrometry have limited reproducibility across
laboratories. It is observed that variability attribu-
table to instrumentation has been confounded by
differences in sample collection, data processing
and analysis methods. Thus, researchers view
these technologies as a rapid screening tool for
generating profiles but difficult for routine
screening application. It is essential to develop
simpler detection kits for this battery of markers
using low-throughput techniques, such as ELISA,
multiwestern assays, protein arrays which are
feasible to perform in clinical laboratories at an
affordable price.
As diagnostic and prognostic markers need
validation, precaution needs to be taken before a
differentiator is declared as a molecular target for
therapy. Although the biomarkers prove to be
discriminators between disease states, that
should not be extrapolated as the reflection of its
role in the mechanism of disease and thus view it
as a potential drug target. This requires integra-
tion of the information with relevant biology.
SUMMARY
Global profiling in general and proteomics in
particular, has great potential for providing
molecular signatures, which could be used for
diagnosis, prognosis, for monitoring response to
therapy as well as in identifying new therapeutic
targets. The success at the bench is poised to be
taken to the bedside with a lot more precision in
analyses.
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